| Literature DB >> 25350546 |
Julia R G Raifman1, Heather E Lanthorn2, Slawa Rokicki3, Günther Fink1.
Abstract
BACKGROUND: Low rates of adherence to artemisinin-based combination therapy (ACT) regimens increase the risk of treatment failure and may lead to drug resistance, threatening the sustainability of current anti-malarial efforts. We assessed the impact of text message reminders on adherence to ACT regimens.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25350546 PMCID: PMC4211682 DOI: 10.1371/journal.pone.0109032
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Study Flow.
Notes: 1792 of 3317 screened individuals were eligible to participate in the study. The most common reasons for exclusion were living more than a 30-minute drive from the ACT vendor and not having a mobile phone, followed by purchasing drugs for somebody who was not a member of the same household. Of those eligible for study participation, 1140 enrolled with the same mobile phone number that they shared with data enumerators, of whom 554 were randomized to the control group, 277 to the reminder-only message group, and 309 to the reminder and additional information message group. A total of 1110 participants reported on their ACT adherence and were included in the main analysis.
Sample Characteristics.
| Control | Treatment | Eligible but without mobile match | Ineligible | |||||
| n | % (SD) | n | % (SD) | n | % (SD) | n | % (SD) | |
| Patient is male | 213 | 46.6 (73.9) | 225 | 44.3 (70.5) | 301 | 40.3 (79.7) | ||
| Patient age <5 | 76 | 13.7 (35.2) | 97 | 16.5 (36.6) | 94 | 14.8 (32.3) | 239 | 16.6 (36.4) |
| Patient age 5–17 | 90 | 16.3 (36.6) | 124 | 21.1 (41.0) | 110 | 17.3 (36.6) | 304 | 21.1 (40.0) |
| Patient age 18–59 | 350 | 63.4 (48.3) | 329 | 56.1 (49.6) | 390 | 61.4 (49.9) | 800 | 55.5 (50.0) |
| Patient age 60+ | 31 | 5.6 (23.4) | 23 | 3.9 (20.6) | 41 | 6.5 (23.1) | 99 | 6.9 (24.6) |
| Male household head | 498 | 89.9 (30.2) | 511 | 87.2 (33.4) | 571 | 87.6 (33.0) | 1311 | 85.9 (34.7) |
| Head of hh: no education | 202 | 39.8 (48.1) | 226 | 42.1 (48.7) | 237 | 40.5 (48.1) | 641 | 48.8 (49.4) |
| Head of hh: some education | 200 | 39.4 (48.1) | 209 | 38.9 (47.9) | 207 | 35.4 (46.5) | 408 | 31.1 (44.2) |
| Head of hh: higher education | 106 | 20.9 (39.4) | 102 | 19.0 (37.9) | 141 | 24.1 (41.2) | 264 | 20.1 (37.8) |
| Household poorest quintile | 107 | 19.3 (39.5) | 102 | 17.5 (37.9) | 99 | 15.2 (35.9) | 352 | 23.7 (34.7) |
| Household second quintile | 100 | 18.1 (38.5) | 94 | 16.1 (36.7) | 133 | 20.4 (40.3) | 324 | 21.8 (42.1) |
| Household third quintile | 122 | 22.1 (41.5) | 137 | 23.5 (42.4) | 134 | 20.6 (40.4) | 265 | 17.8 (40.1) |
| Household fourth quintile | 115 | 20.8 (40.6) | 136 | 23.3 (42.3) | 137 | 20.1 (40.8) | 266 | 17.9 (37.9) |
| Household wealthiest quintile | 109 | 19.7 (39.8) | 114 | 19.6 (39.6) | 146 | 21.0 (41.7) | 280 | 18.8 (37.9) |
| Artemether Lumefantrine | 317 | 51.3 (49.5) | 326 | 55.6 (49.7) | 379 | 58.1 (49.4) | 782 | 51.3 (50.0) |
| Artesunate Amodiaquine | 147 | 26.5 (44.2) | 169 | 28.8 (45.3) | 189 | 29.0 (45.4) | 435 | 28.5 (45.2) |
| Private hospital | 128 | 23.4 (42.4) | 129 | 22.3 (41.7) | 176 | 27.8 (44.8) | 354 | 23.9 (42.6) |
| Private clinic | 54 | 9.9 (29.9) | 50 | 8.7 (28.1) | 44 | 6.9 (25.4) | 142 | 9.6 (29.4) |
| Public hospital | 78 | 14.3 (35.0) | 90 | 15.6 (36.2) | 95 | 15.0 (35.7) | 226 | 15.2 (40.0) |
| Public clinic | 120 | 21.9 (41.4) | 131 | 22.7 (41.4) | 134 | 21.1 (40.9) | 382 | 25.8 (43.7) |
| Pharmacy | 13 | 2.4 (15.2) | 11 | 1.9 (13.7) | 12 | 1.9 (13.6) | 23 | 1.6 (12.4) |
| Licensed Chemical Seller | 139 | 25.4 (4.4) | 152 | 26.3 (44.1) | 168 | 26.5 (44.2) | 311 | 21.0 (40.7) |
Notes: n is the number of participants in each group who have each characteristic, such as age younger than five years. The denominator for each measure differs based on the number of participants for which an answer was recorded. We did not inquire about patient sex in the screening interview and do not have this information for individuals who were not eligible to participate in the study.
Figure 2Dose completion among adults in the control group.
Notes: Figure 2 indicates the proportion of adults in the control group who reported taking each dose of treatment in the per-dose self-report. Among 239 adults who took AL and reported per-dose adherence, 200 (83.7%) reported taking the fourth dose, 174 (72.8%) reported taking the fifth dose, and 135 (56.5%) reported taking the sixth dose. Among 70 adults in the control group taking AS+AQ, 33 (47.9%) reported completing the full three-dose regimen.
Effect of text message treatment on self-reported adherence.
| Percent completed treatment | Adjusted OR(95% CI) | |
|
| 61.5 | Reference Group |
|
| 66.4 | 1.45** |
| (1.03–2.04) | ||
|
| 64.1 | 0.77 |
| (0.50–1.20) | ||
|
| 1110 | 1110 |
Notes: Covariates are all those listed in Table 1, including sex and age of the patient, and household characteristics. **p<0.05.
Per-protocol Subgroup Analysis.
| Control | Reminder text message | Long message | |||
| Proportionadhering (%) | Proportionadhering (%) | Adjusted OR(95% CI) | Proportionadhering (%) | AdjustedOR (95% CI) | |
|
| |||||
|
|
|
|
|
|
|
| (N) | (164) | (215) | (1.01–5.26) | (112) | (0.20–0.99) |
|
|
|
|
|
|
|
| (N) | (373) | (352) | (0.92–1.72) | (189) | (0.64–1.42) |
|
| |||||
|
|
|
|
|
|
|
| (N) | (206) | (220) | (0.86–2.13) | (116) | (0.4–1.74) |
|
|
|
|
|
|
|
| (N) | (238) | (278) | (1.20–3.75) | (147) | (0.28–1.18) |
|
| |||||
|
|
|
|
|
|
|
| (N) | (195) | (218) | (1.14–3.56) | (109) | (0.23–0.82) |
|
|
|
|
|
|
|
| (N) | (197) | (205) | (0.67–2.24) | (105) | (0.63–3.36) |
|
|
|
|
|
|
|
| (N) | (101) | (100) | (0.57–3.37) | (59) | (0.18–1.21) |
|
| |||||
|
|
|
|
|
|
|
| (N) | (105) | (101) | (0.37–2.85) | (50) | (0.43–4.24) |
|
|
|
|
|
|
|
| (N) | (98) | (93) | (1.09–5.96) | (50) | (0.18–1.23) |
|
|
|
|
|
|
|
| (N) | (118) | (131) | (0.77–3.69) | (41) | (0.44–1.89) |
|
|
|
|
|
|
|
| (N) | (110) | (133) | (1.05–2.98) | (78) | (0.25–0.66) |
|
|
|
|
|
|
|
| (N) | (106) | (111) | (0.63–2.63) | (61) | (0.27–3.16) |
|
| |||||
|
|
|
|
|
|
|
| (138) | (147) | (0.44–1.40) | (76) | (0.75–3.04) | |
|
|
|
|
|
|
|
|
| (54) | (48) | (1.47–2.91) | (24) | (0.60–0.88) |
|
|
|
|
|
|
|
|
| (122) | (128) | (1.54–2.60) | (66) | (0.29–0.52) |
|
|
|
|
|
|
|
|
| (76) | (89) | (0.81–3.53) | (44) | (0.19–0.69) |
| (N) | |||||
|
|
|
|
|
|
|
|
| (118) | (126) | (0.91–2.13) | (44) | (0.28–1.85) |
| (N) | |||||
|
| |||||
|
|
|
|
|
|
|
| (N) | (305) | (320) | (0.88–2.59) | (174) | (0.34–1.33) |
|
|
|
|
|
|
|
| (N) | (144) | (163) | (1.17–4.30) | (79) | (0.22–0.78) |
Notes: N is the number of people in each subgroup, such as the number of children whose caregivers received the simple reminder message. Covariates are all those listed in Table 1, including sex and age of the patient, and household and facility type. There were fewer than 30 individuals in the main analysis who received ACTs from pharmacies, health posts, CHPs zones, or health professionals’ homes. ***p<0.01, **p<0.05.
Self-reported treatment completion and remaining pills or ACT Stock.
| Participant reports treatment completion(N = 711) | Participant reports incomplete treatment(N = 399) | |
|
| 6.4 | 97.9 |
|
| 37.1 | 72.1 |
Notes: The proportion of participants who reported adherence and non-adherence and who either had pills remaining in an observed packet or had an ACT stock in the home. Enumerators observed pill packets for 667 (60.1%) participants and drug stocks for 929 (83.7% of) participants.
Effect of treatment on still feeling sick.
| Proportion completed treatment% | Adjusted OR(95% CI) | |
|
| 29.5 | Reference group |
|
| 30.9 | 1.06 |
| (0.78–1.45) | ||
|
| 30.7 | 1.02 |
| (0.79–1.30) | ||
|
| 1110 | 1110 |
Notes: Patients reported still feeling sick at the time of the follow-up interview. Logistic regression includes the full set of covariates listed in Table 1, including sex and age of the patient, household and facility characteristics.